|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Asenapine maleate]] |
| | IUPAC_name = (3a''S'',12b''S'')-5-Chloro-2,3,3a,12b-tetrahydro-<br>2-methyl-1''H''-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
| |
| | image = Asenapine.png
| |
| | CAS_number = 65576-45-6
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem = 163091
| |
| | DrugBank =
| |
| | C = 17 | H = 16 | Cl = 1 | N = 1 | O = 1
| |
| | molecular_weight = 285.77 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category=
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| | |
| '''Asenapine''' is a new [[5-HT2A receptor|5-HT<sub>2A</sub>-]] and [[dopamine receptor|D2-receptor]] [[antagonist]] under development for the treatment of [[schizophrenia]] and acute mania associated with [[bipolar disorder]] by [[Schering-Plough]] after its [[November 19]], [[2007]] combination with [[Organon International]]. Development of the drug, through [[Phase III]] trials, began while Organon was still a part of [[Akzo Nobel]].<ref name="GEN200706">{{cite news
| |
| | title = Bipolar Disorder | work = Clinical Trials Update
| |
| | publisher = Genetic Engineering & Biotechnology News | pages = 52,55 | date = 2007-06-15 | accessdate = 2007-12-16
| |
| }}</ref> Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in [[clinical trial]]s of asenapine, and the [[Food and Drug Administration|FDA]] accepted the manufacturer's [[New Drug Application|NDA]] on [[November 26]], [[2007]] for standard review. <ref>{{cite press release
| |
| | title = Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
| |
| | publisher = Schering-Plough
| |
| | date = [[2007-11-26]]
| |
| | url = http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1080771
| |
| | accessdate = 2007-11-26 }})</ref>
| |
| | |
| Asenapine belongs to a class of neuroleptics known as "[[atypical antipsychotics]]", which have, over the last two decades, become increasingly popular alternatives to "[[typical antipsychotics]]", such as [[haloperidol]]. The manufacturers of asanapine refer to it as a "new generation" or "second generation" atypical antipsychotic.
| |
| | |
| Other atypical antipsychotics include [[aripiprazole]], [[olanzapine]], [[quetiapine]], [[risperidone]], and [[ziprasidone]].
| |
| | |
| | |
| ==Notes==
| |
| | |
| <references />
| |
| | |
| ==External links==
| |
| | |
| ===Commercial===
| |
| * [http://www.organon.com/ Organon website]
| |
| | |
| ===Third-party===
| |
| * [http://www.medicalnewstoday.com/medicalnews.php?newsid=57683 Organon Continues With The Development Of Asenapine For Schizophrenia And Acute Mania Associated With Bipolar I Disorder]
| |
| | |
| [[Category:Receptor modulators]]
| |
| {{Antipsychotics}}
| |
| | |
| <!--Categories-->
| |
| [[Category:Atypical antipsychotics]]
| |
| | |
| | |
| | |
| {{pharma-stub}}
| |